Latest Commercialisation News

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

Iondrive Limited has advanced its battery recycling ambitions by securing key partnerships in the US and Australia, commencing pilot plant construction, and gaining substantial government funding support.

Magnum Mining & Exploration has partnered with Homerun Resources to explore innovative, environmentally friendly rare earth element separation technology using ultra-pure silica sand and graphite. This collaboration could reshape processing methods for Magnum’s Brazilian REE projects.

Parkway Corporate Limited reports a robust start to FY26 with strong operating revenue and EBITDA, alongside securing a pivotal 10-hectare site for its Queensland Brine Management Complex project.

Condor Energy secures a 12-month extension for its offshore Peru exploration block and validates the Piedra Redonda gas field as a key regional energy asset with multiple commercialisation options.

Elevate Uranium has shipped its U-pgrade pilot plant to Namibia for commissioning and continues to expand uranium mineralisation at its Namib IV prospect. The company also moves to divest its Oobagooma project, sharpening its strategic focus.

Hydrocarbon Dynamics Limited has reactivated its North Sea trial and completed a fully underwritten rights issue raising $718,741, while advancing multiple international projects and exploring new energy ventures.

ADX Energy Ltd is gearing up to restart flow testing at Welchau-1 and drill multiple shallow gas and oil wells in Upper Austria starting January 2026, aiming for a significant boost in production from low-risk prospects.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Ashley Services reported a challenging FY25 with a 7.3% revenue decline but kicked off FY26 with record quarterly revenues and improved profitability, signaling a strategic turnaround.

Anteris Technologies has enrolled the first patients in its pivotal PARADIGM Trial, testing the DurAVR Transcatheter Heart Valve against leading competitors in a global study.